Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. The results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma.
The significance of these findings lies in the potential for Telomir-Zn to address osteosarcoma, a rare and aggressive bone cancer that affects both humans and dogs. Osteosarcoma is the most common primary bone tumor in children and adolescents, and it also occurs frequently in dogs, particularly in larger breeds. The fact that Telomir-Zn demonstrated similar growth inhibition in both human and canine cell lines at low concentrations suggests a conserved mechanism of action that could be exploited therapeutically across species. This cross-species activity is particularly valuable because it allows researchers to use naturally occurring canine osteosarcoma as a translational model for human disease, potentially accelerating drug development.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. If successful, this approach could lead to a new treatment option for dogs with osteosarcoma, while also providing critical data to inform human clinical trials. The company said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared IND for advanced or metastatic TNBC. This prioritization underscores the company's strategic approach to allocate resources efficiently while exploring additional indications for Telomir-Zn.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. The new osteosarcoma data add to the growing body of evidence supporting Telomir-Zn's potential across multiple cancer types.
For investors, the announcement highlights the broadening potential of Telomir-Zn beyond its lead indication. Osteosarcoma represents a significant unmet medical need, with limited treatment options and poor outcomes for patients with metastatic disease. The possibility of developing a therapy that could benefit both human and veterinary patients opens up a dual-market opportunity, which could enhance the commercial prospects of Telomir-Zn. Moreover, the use of canine osteosarcoma as a translational model may provide a faster and more cost-effective route to human clinical trials, as canine trials can yield valuable efficacy and safety data that may be more predictive of human outcomes than traditional rodent models.
The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO. To view the full press release, visit https://nnw.fm/laeGH. For more information about NetworkNewsWire, visit https://www.NetworkNewsWire.com.
